Maxcyte Inc News Today

MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) CEO Maher Masoud acquired 70,443 shares of the stock in a transaction dated Monday, June 10th. The stock was bought at an average cost of $4.90 per share, with a total value of $345,170.70. Following the completion of the purchase, the chief executive officer now owns 100,000 shares […]

Cadian Capital Management LP bought a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,644,898 shares of the company’s stock, valued at approximately $26,531,000. MaxCyte comprises 1.1% of Cadian Capital […]

Cadian Capital Management LP acquired a new position in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,644,898 shares of the company’s stock, valued at approximately $26,531,000. MaxCyte comprises about 1.1% of Cadian […]

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference Rockville, MD, May 29, 2024- MaxCyte, Inc., , a leading, cell-engineering focused...

Investegate announcements from Participation in Upcoming Investor Conference

IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply | Financial News

Key Insights Significantly high institutional ownership implies MaxCyte's stock price is sensitive to their trading...

Investegate announcements from Signing of Strategic Platform License

MaxCyte, Inc. announced it has entered into a strategic platform license agreement with Legend Biotech. Under the terms of the SPL, Legend Biotech obtains a non-exclusive worldwide license to use...

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing next-generation cell therapeutics - Inks strategic platform license agreement with Legend Biotech...